Nuglim M2 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This dual mechanism addresses both insulin deficiency and insulin resistance, making Nuglim M2 Forte effective for patients inadequately controlled on diet and exercise alone or those requiring combination therapy. The prolonged-release formulation ensures sustained drug release, promoting stable plasma concentrations and improving patient compliance by reducing dosing frequency. Nuglim M2 Forte should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea and diarrhea. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and potential hypoglycemic episodes is essential during therapy. Nuglim M2 Forte Tablet PR is a valuable therapeutic option for optimizing glycemic control in type 2 diabetes, contributing to the reduction of microvascular and macrovascular complications associated with chronic hyperglycemia.

Dosage & How to Use